Dihydroorotate dehydrogenase inhibition acts synergistically with tyrosine kinase inhibitors to induce apoptosis of mantle cell lymphoma cells. Issue 3 (15th May 2022)

• Record Type: Journal Article
• Authors: Eriksen‐Gjerstad, May; Tveit Karlsen, Ida; Fandalyuk, Zinayida; Benjaminsen, Susanne; Baran‐Marszak, Fanny; Papp, Bela; Locke, Frederick; Ladds, Marcus; Pastor‐Fernández, Andrés; Gelebart, Pascal; Mc Cormack, Emmet
• Is Part Of: EJHaem. Volume 3:Issue 3(2022)
• Page Start: 913
• Page End: 918
• Publication Date: 2022-05-15
• Subjects: apoptosis -- DHODH -- mantle cell lymphoma -- targeted therapy; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.434
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma that remains incurable with the treatment options available today. In the present study, we have identified the dihydroorotate dehydrogenase (DHODH), an essential enzyme for the de novo biosynthesis of pyrimidine‐based nucleotides, to be overexpressed in MCL in comparison to healthy peripheral blood mononuclear cells (PBMC). In vitro inhibition of the DHODH activity using a newly developed DHODH inhibitor, namely ( R )‐HZ05, can induce MCL cell death in the nanomolar range independently than the P53 status of the investigated cell lines. Moreover, the combination of ( R )‐HZ05 with tyrosine kinase inhibitor shows the synergistic activity on cell death. Pre‐clinical investigation on the efficacy of ( R )‐HZ05 shows that it can be prolonged animal lifespan similar to ibrutinib. ( R )‐HZ05 use in combination with tyrosine kinase inhibitor demonstrated a superior efficacy on tumor burden reduction and survival than either drug alone. We have demonstrated that the depletion of the pyrimidine nucleotide pool, using DHODH inhibitor, represents a new therapeutic strategy that may benefit MCL patients.